SCHEDULE: Rosalind Entities Disclose Significant Fennec Pharma Stake

Rosalind Advisors, Rosalind Master Fund, and associated individuals have reported beneficial ownership exceeding 9% in Fennec Pharmaceuticals Inc.

Summary

• Rosalind Advisors, Inc. and affiliated entities, including Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon, have disclosed significant beneficial ownership in Fennec Pharmaceuticals Inc.
• Rosalind Advisors, Inc. beneficially owns 2,746,840 common shares, representing 9.8% of the class.
• Steven Salamon and Gilad Aharon each beneficially own 2,680,174 common shares, representing 9.5% of the class.
• Rosalind Master Fund L.P. beneficially owns 2,613,508 common shares, representing 9.3% of the class.
• The percentages are based on 28,116,829 ordinary shares outstanding as of November 10, 2025.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive. The disclosure of a significant, non-control-seeking stake by an investment advisor and fund suggests confidence in Fennec Pharmaceuticals' long-term value proposition.

Positives

• Significant institutional and individual investor confidence demonstrated by a substantial stake in Fennec Pharmaceuticals Inc.
• The filing indicates a long-term investment strategy, as the securities are held in the ordinary course of business and not for control purposes.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that significant beneficial ownership disclosures, particularly from investment advisors and funds, often signal a belief in the long-term value or strategic potential of a company within its sector. For Fennec Pharmaceuticals, a company in the pharmaceutical industry, such a stake could be interpreted as a positive signal regarding its drug pipeline, market position, or overall business strategy, especially given the capital-intensive nature of the sector.

Comparison to Industry Standards

• StockSavvy.ai observes that institutional ownership levels vary significantly across the pharmaceutical industry, often correlating with a company's stage of development, market capitalization, and perceived risk profile. A 9%+ stake from a single investment group, while not uncommon for smaller-cap companies, represents a substantial commitment. For example, similar significant stakes are often seen in emerging biotech firms where specialized funds take concentrated positions, such as the early investments by Baker Bros. Advisors in companies like Incyte or Seagen, or by Perceptive Advisors in various clinical-stage biotechs. This level of ownership suggests a high conviction in Fennec Pharmaceuticals' prospects, potentially aligning with a strategy to support growth or influence governance without seeking outright control.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence among existing shareholders and attract new investors, potentially influencing share price positively.
• Management: Management may view this as a vote of confidence from a significant investor, potentially aligning interests for long-term value creation.

Key Dates

Recommendation

The filing indicates a significant institutional stake, which is generally a positive signal of investor confidence. However, a Schedule 13G filing primarily discloses ownership and does not provide operational or financial performance updates. Without additional information on Fennec Pharmaceuticals' recent financial results, strategic developments, or market conditions, a "hold" recommendation is prudent. The substantial stake suggests a belief in the company's long-term value, but it doesn't inherently warrant a "buy" without further fundamental analysis.

Keywords

Fennec Pharmaceuticals, Rosalind Advisors, Rosalind Master Fund, Steven Salamon, Gilad Aharon, beneficial ownership, Schedule 13G, common shares, institutional investment, pharmaceuticals